BioRestorative Therapies, Inc.

BRTX Nasdaq SEC CIK 1505497
Follow BioRestorative Therapies Weekly email: filings, results

Financials

Reported figures only · latest: Q1 2026 USD · US GAAP
Revenue, last quarter $23.2K −7.3% vs same quarter last year
Net income −$2.2M +59.7% vs same quarter last year
EPS, diluted −$0.12 +81.3% vs same quarter last year
Operating cash flow −$3.8M −37% vs same quarter last year
Revenue by quarter
$89.1K
$233.6K
$43.3K
$25K
$303.3K
$11.8K
$19.6K
$23.2K
Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$60M−$40M−$20M$0$20MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$359.7K−$14.2M
FY24$401K−$9M
FY23$145.8K−$10.4M
FY22$119.8K−$13.2M
FY21$46K−$44.3M
FY20$77K−$11.3M
FY19$130K−$14.6M
FY18$111K−$12.5M
FY17$81K−$9.4M
FY16$36.4K−$8.6M
FY15$628.9K−$7.9M
FY14$416K−$5.6M
FY13$1.7K−$5.8M
FY12$15.6K−$6.5M
FY11$0−$4.1M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−400000%−300000%−200000%−100000%0%100000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2593.4%−4350.1%−3959.4%
FY2493%−2881.6%−2239.2%
FY23100%−10439.5%−7145.2%
FY22-−15838.1%−11037%
FY21-−57191%−96311.5%
FY20-−3574.1%−14639.9%
FY19-−6486.2%−11267.6%
FY18-−6889.8%−11277.3%
FY17100%−10338.6%−11660.1%
FY1699.7%−21414%−23755.4%
FY1558.4%−1140.1%−1259.9%
FY1448.6%−1183.3%−1343.2%
FY1387.6%−282873.2%−342333%
FY1291.6%−35746.1%−41931.6%
FY11---
Free cash flowOperating cash flow minus capital expenditure
−$15M−$10M−$5M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$10.9M
FY24−$8.3M
FY23−$6.6M
FY22−$6.2M
FY21−$3.4M
FY20-
FY19−$7M
FY18−$5.1M
FY17−$3.9M
FY16−$5.2M
FY15−$3.5M
FY14−$3.4M
FY13−$2.7M
FY12−$3.2M
FY11−$2.8M
Returned to shareholdersDividends paid and shares bought back
$0$1K$2K$3K$4KFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25$0
FY24-
FY23-
FY22-
FY21-
FY20-
FY19-
FY18-
FY17-
FY16-
FY15-
FY14-
FY13$0
FY12$0
FY11$4K
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • BioRestorative Therapies
  • Healthcare median
−400000%−300000%−200000%−100000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBioRestorative TherapiesHealthcare median
FY25−3959.4%−30.6%
FY24−2239.2%−47%
FY23−7145.2%−58%
FY22−11037%−80.4%
FY21−96311.5%−71.9%
FY20−14639.9%−62.2%
FY19−11267.6%−46.3%
FY18−11277.3%−49.6%
FY17−11660.1%−45.9%
FY16−23755.4%−36%
FY15−1259.9%−38.4%
FY14−1343.2%−35.5%
FY13−342333%−37.1%
FY12−41931.6%−29.1%
FY11-−27.9%